A CD133 targeting toxin and a CD133 BiKE which were constructed with the same CD133 binding site as the TetraKE showed good response rates in CD133+ bearing ovarian, gastrointestinal and breast cancer [23, 42–44] even when the CD133+ population was <10% CD133+ cells. This evidence concerns the gene PROM1 and breast cancer.